Safety, Tolerability, and Pharmacokinetics of RT234 (Vardenafil Inhalation Powder): A First-in-Human, Ascending Single- and Multiple-Dose Study in Healthy Subjects

Background: RT234 (vardenafil inhalation powder) is being developed for pulmonary administration “as needed”, to acutely improve exercise tolerance and symptoms in patients with pulmonary arterial hypertension (PAH). Methods: This single-center, open-label, randomized study in 32 healthy adult subje...

Descripción completa

Detalles Bibliográficos
Autores principales: Eldon, Michael A., Parsley, Edwin L., Maurer, Mari, Tarara, Thomas E., Okikawa, Jerry, Weers, Jeffry G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8377511/
https://www.ncbi.nlm.nih.gov/pubmed/33325799
http://dx.doi.org/10.1089/jamp.2020.1651

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8377511/
https://www.ncbi.nlm.nih.gov/pubmed/33325799
http://dx.doi.org/10.1089/jamp.2020.1651

Ejemplares similares